Tokyo, Nov. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059734) titled 'Tolerability of sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy and evaluation of the diagnostic accuracy of contrast-enhanced CT for lymph node metastasis' on Nov. 11.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Osaka City General Hospital
Condition:
Condition - Breast cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Evaluation of sentinel lymph node biopsy for acquired clinical node-negative breast cancer after neoadjuvant therapy in node-positive breast cancer.
Evaluation of the diagnostic accuracy of contrast-enhanced CT for lymph node metastasis.
Basic objectives2 - Safety,Efficacy
Intervention:
Interventions/Control_1 - Sentinel lymph node biopsy
Eligibility:
Age-lower limit - 20
years-old
<
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Aquired clinical node negative breast cancer after neoadjuvant therapy
Key exclusion criteria - Inoperable case
Inflammatory breast cancer
Target Size - 64
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2021 Year 04 Month 30 Day
Date of IRB - 2021 Year 05 Month 11 Day
Anticipated trial start date - 2021 Year 07 Month 19 Day
Last follow-up date - 2033 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067286
Disclaimer: Curated by HT Syndication.
